Colorectal cancer has been a leading cause of cancer-related morbidity and mortality. For the research and individualization of therapy, primary cell lines of the colorectal cancer appear to be still an invaluable tool. We evaluated the differences in metastatic potential between four isolated primary colon cancer cells and cells derived from their lymph node metastasis. These results were compared with correspond immortalized cells—SW480 and SW620, respectively. The ability to migrate was tested using real-time measurement in xCELLigence system. Expressions of molecules involved in adhesion and invasion processes were examined using RT-PCR and western blot analysis. Furthermore, impact of cytotoxic effect of selected chemotherapeutics (irinotecan, oxaliplatin) and biological therapy (bevacizumab, cetuximab, panitumumab) was assessed by the WST assay. As expected, cell lines derived from lymph node migrated more aggressively and higher expression of adhesion molecules ICAM-1, EpCAM, and N-cadherin was detected. The expression of MMP-2 and -9 was elevated, on the other hand, in cell lines derived from primary tumor cancer cells as well as the expression of miR-21, miR-29a, and miR-200a. The most pronounced cytotoxic effect has been recorded with oxaliplatin and irinotecan (IC50 = 48.23 resp. 0.11 μg/ml), especially in cells originating from lymph node metastases. In total, comparison of isolated cell lines and immortalized cell lines has shown many similarities, as well as several differences. Adhesion/invasion molecules and several miRNAs, which play an important role in tumor development and the invasive and migratory behavior, could be a useful therapeutic target in malignant colorectal cancer.
This is a preview of subscription content, log in to check access.
The authors would like to thank Svetlana Kopecka for her laboratory support in preparation of cell lines. This work was supported by Ministry of Health—Czech Republic, project IGA No. NT14150-3/2013.
Compliance with ethical standards
Conflict of interest
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
Tang R, Wang JY, Chen JS, Chang-Chien CR, Tang S, Lin SE, et al. Survival impact of lymph node metastasis in TNM stage III carcinoma of the colon and rectum. J Am Coll Surg. 1995;180(6):705–12.PubMedGoogle Scholar
Kaneko I, Tanaka S, Oka S, Kawamura T, Hiyama T, Ito M, et al. Lymphatic vessel density at the site of deepest penetration as a predictor of lymph node metastasis in submucosal colorectal cancer. Dis Colon Rectum. 2007;50(1):13–21. doi:10.1007/s10350-006-0745-5.CrossRefPubMedGoogle Scholar
Palomares T, Alonso-Varona A, García-Alonso I, Portugal V. New strategies to enhance the efficacy of surgical treatment for colorectal liver metastasis. Colorectal Cancer - Surgery, Diagnostics and Treatment. 2014.Google Scholar
Aamodt R, Bondi J, Andersen SN, Bakka A, Bukholm G, Bukholm IR. The prognostic impact of protein expression of E-cadherin-catenin complexes differs between rectal and colon carcinoma. Gastroenterol Res Pract. 2010. doi:10.1155/2010/616023.PubMedPubMedCentralGoogle Scholar
Ikeguchi M, Taniguchi T, Makino M, Kaibara N. Reduced E-cadherin expression and enlargement of cancer nuclei strongly correlate with hematogenic metastasis in colorectal adenocarcinoma. Scand J Gastroenterol. 2000;35(8):839–46.CrossRefPubMedGoogle Scholar
Lugli A, Zlobec I, Minoo P, Baker K, Tornillo L, Terracciano L, et al. Prognostic significance of the wnt signalling pathway molecules APC, beta-catenin and E-cadherin in colorectal cancer: a tissue microarray-based analysis. Histopathology. 2007;50(4):453–64. doi:10.1111/j.1365-2559.2007.02620.x.CrossRefPubMedGoogle Scholar
Roca F, Mauro LV, Morandi A, Bonadeo F, Vaccaro C, Quintana GO, et al. Prognostic value of E-cadherin, beta-catenin, MMPs (7 and 9), and TIMPs (1 and 2) in patients with colorectal carcinoma. J Surg Oncol. 2006;93(2):151–60. doi:10.1002/jso.20413.CrossRefPubMedGoogle Scholar
Ye Z, Zhou M, Tian B, Wu B, Li J. Expression of lncRNA-CCAT1, E-cadherin and N-cadherin in colorectal cancer and its clinical significance. Int J Clin Exp Med. 2015;8(3):3707–15.PubMedPubMedCentralGoogle Scholar
Zhuo HQ, Jiang KW, Dong LY, Zhu Y, Lu L, Lu Y, et al. Overexpression of N-cadherin is correlated with metastasis and worse survival in colorectal cancer patients. Chin Sci Bull. 2013;58(28-29):3529–34. doi:10.1007/s11434-013-5813-3.CrossRefGoogle Scholar
Moutasim K, Nystrom M, Thomas G (2011) Cell migration and invasion assays. In: Cree IA (ed) Cancer cell culture, vol 731. Methods in molecular biology. Humana Press, pp 333-343. doi:10.1007/978-1-61779-080-5_27
Cree I (2011) Principles of cancer cell culture. In: Cree IA (ed) Cancer cell culture, vol 731. Methods in molecular biology. Humana Press, pp 13-26. doi:10.1007/978-1-61779-080-5_2
Ljung BM, Mayall B, Lottich C, Boyer C, Sylvester SS, Leight GS, et al. Cell dissociation techniques in human breast cancer—variations in tumor cell viability and DNA ploidy. Breast Cancer Res Treat. 1989;13(2):153–9.CrossRefPubMedGoogle Scholar
Brunet Vega A, Pericay C, Moya I, Ferrer A, Dotor E, Pisa A, et al. microRNA expression profile in stage III colorectal cancer: circulating miR-18a and miR-29a as promising biomarkers. Oncol Rep. 2013;30(1):320–6. doi:10.3892/or.2013.2475.PubMedGoogle Scholar
Omrane I, Benammar-Elgaaied A. The immune microenvironment of the colorectal tumor: involvement of immunity genes and microRNAs belonging to the TH17 pathway. Biochim Biophys Acta. 2015;1856(1):28–38. doi:10.1016/j.bbcan.2015.04.001.PubMedGoogle Scholar
Failli A, Consolini R, Legitimo A, Spisni R, Castagna M, Romanini A, et al. The challenge of culturing human colorectal tumor cells: establishment of a cell culture model by the comparison of different methodological approaches. Tumori. 2009;95(3):343–7.PubMedGoogle Scholar
Nakajima S, Doi R, Toyoda E, Tsuji S, Wada M, Koizumi M, et al. N-cadherin expression and epithelial-mesenchymal transition in pancreatic carcinoma. Clin Cancer Res Off J Ame Assoc Cancer Res. 2004;10(12 Pt 1):4125–33. doi:10.1158/1078-0432.CCR-0578-03.CrossRefGoogle Scholar
Tsanou E, Peschos D, Batistatou A, Charalabopoulos A, Charalabopoulos K. The E-cadherin adhesion molecule and colorectal cancer. A global literature approach. Anticancer Res. 2008;28(6A):3815–26.PubMedGoogle Scholar
Maeda K, Kang SM, Sawada T, Nishiguchi Y, Yashiro M, Ogawa Y, et al. Expression of intercellular adhesion molecule-1 and prognosis in colorectal cancer. Oncol Rep. 2002;9(3):511–4.PubMedGoogle Scholar
Kelly CP, O'Keane JC, Orellana J, Schroy 3rd PC, Yang S, LaMont JT, et al. Human colon cancer cells express ICAM-1 in vivo and support LFA-1-dependent lymphocyte adhesion in vitro. The American journal of physiology. 1992;263(6 Pt 1):G864–70.PubMedGoogle Scholar
Zhang YY, Chen B, Ding YQ. Metastasis-associated factors facilitating the progression of colorectal cancer. Asian Pac J Cancer Prev: APJCP. 2012;13(6):2437–44.CrossRefPubMedGoogle Scholar
Zucker S, Vacirca J. Role of matrix metalloproteinases (MMPs) in colorectal cancer. Cancer Metastasis Rev. 2004;23(1-2):101–17.CrossRefPubMedGoogle Scholar
Kheirelseid EAH, Miller N, Chang KH, Nugent M, Kerin MJ. Clinical applications of gene expression in colorectal cancer. J Gastrointest Oncol. 2013;4(2):144–57.PubMedPubMedCentralGoogle Scholar
Triulzi T, Tagliabue E, Casalini P, Iorio MV. microRNA: New Players in Metastatic Process. Oncogene and Cancer - From Bench to Clinic. 2013.Google Scholar
Berrino F, De Angelis R, Sant M, Rosso S, Lasota MB, Coebergh JW, et al. Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995–99: results of the EUROCARE-4 study. Lancet Oncol. 2007;8(9):773–83. doi:10.1016/S1470-2045(07)70245-0.CrossRefPubMedGoogle Scholar
Dahan L, Sadok A, Formento JL, Seitz J, Kovacic H. Modulation of cellular redox state underlies antagonism between oxaliplatin and cetuximab in human colorectal cancer cell lines. Br J Pharmacol. 2009;158(2):610–20.CrossRefPubMedPubMedCentralGoogle Scholar
Saltz LB, Niedzwiecki D, Hollis D, Goldberg RM, Hantel A, Thomas JP, et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol: Off J Ame Soc Clin Oncol. 2007;25(23):3456–61. doi:10.1200/JCO.2007.11.2144.CrossRefGoogle Scholar
Van Cutsem E, Labianca R, Bodoky G, Barone C, Aranda E, Nordlinger B, et al. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009;27(19):3117–25.CrossRefGoogle Scholar
Arnould S, Hennebelle I, Canal P, Bugat R, Guichard S. Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines. Eur J Cancer. 2003;39(1):112–9.CrossRefPubMedGoogle Scholar
Ikehata M, Ogawa M, Yamada Y, Tanaka S, Ueda K, Iwakawa S. Different effects of epigenetic modifiers on the cytotoxicity induced by 5-fluorouracil, irinotecan or oxaliplatin in colon cancer cells. Biol Pharm Bull. 2014;37(1):67–73. doi:10.1248/bpb.b13-00574.CrossRefPubMedGoogle Scholar
Luca T, Barresi V, Privitera G, Musso N, Caruso M, Condorelli DF, et al. In vitro combined treatment with cetuximab and trastuzumab inhibits growth of colon cancer cells. Cell Prolif. 2014;47(5):435–47. doi:10.1111/cpr.12125.CrossRefPubMedGoogle Scholar